Polycystic ovary syndrome (PCOS)

Research context

PCOS is a common endocrine condition characterised by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology, with a strong metabolic phenotype: insulin resistance is present in a majority of affected individuals, and prevalence of obesity, T2D, dyslipidaemia and MASLD is elevated. GLP-1 receptor agonists have generated growing research interest as a class in PCOS, with reported effects on body weight, HbA1c and — in smaller studies — menstrual regularity and fertility markers. None of the available GLP-1 receptor agonists carry a UK-licensed indication for PCOS at the time of review; existing research sits alongside licensed use for T2D and chronic weight management.

Why this matters metabolically

PCOS sits within the cardiometabolic risk cluster: insulin resistance, visceral adiposity, dyslipidaemia and progression to T2D are all more likely in affected individuals. Weight management is a first-line treatment target in guidelines (e.g., international PCOS guideline consortium), and the emerging GLP-1 evidence base connects PCOS to the broader obesity / metabolic-syndrome research programme. Rigorous randomised evidence in PCOS-specific populations remains limited relative to the T2D and obesity literature.

FAQs

Is any GLP-1 receptor agonist licensed for PCOS in the UK?

No. At the time of review, no GLP-1 receptor agonist holds a UK MHRA licence for polycystic ovary syndrome as a primary indication. Licensed indications for semaglutide, liraglutide, dulaglutide and tirzepatide are type 2 diabetes and chronic weight management. Any use in PCOS is off-label and a prescriber decision.

What does the current PCOS-specific GLP-1 evidence show?

Available randomised evidence in PCOS-specific populations is limited to relatively small studies (typically dozens to low hundreds of participants) reporting weight-loss, insulin-sensitivity and — in some studies — menstrual-regularity effects with liraglutide, semaglutide and combination approaches. These studies are heterogeneous in design, duration and outcome definitions. Larger PCOS-specific randomised trials are needed to establish effect size, durability and clinical outcomes such as fertility and long-term cardiometabolic risk.

How does PCOS overlap with obesity and metabolic syndrome?

A large fraction of individuals with PCOS have insulin resistance and elevated cardiometabolic risk regardless of BMI, and obesity prevalence is higher than in age-matched populations. This is why the broader GLP-1 evidence base in obesity and metabolic syndrome is often extrapolated to PCOS discussions — with the important caveat that extrapolation is not the same as PCOS-specific licensed evidence.

What about GLP-1 medicines and fertility in PCOS?

Weight reduction independent of pharmacology is associated with restored ovulation in some individuals with PCOS. Small studies have reported changes in menstrual regularity and ovulatory-marker parameters with GLP-1 therapy. Any prescribing for individuals who could become pregnant requires an explicit contraception and pre-conception plan because pregnancy is contraindicated in the SmPCs of the licensed GLP-1 receptor agonists. See /safety/glp-1-and-pregnancy for the safety framing.

Where does this fit relative to metformin for PCOS?

Metformin has a long-standing role in metabolic management of PCOS and is referenced in international PCOS guidelines. GLP-1 receptor agonists are not a replacement for guideline-driven care; they represent an active research area with a growing but still-limited PCOS-specific evidence base. Choice of pharmacological approach in PCOS is a prescriber decision integrating individual metabolic profile, weight-management goals, fertility considerations and tolerability.